Breast Cancer

Current or recent use of progestogen-only contraceptives was associated with a “slight” increase in breast cancer risk, according to findings from a nested case-control study and meta-analysis published in PLOS Medicine.

For medicine to advance, entrenched paradigms must yield to new evidence. The widely held belief that menopausal hormone therapy causes breast cancer, and thus should never be given to breast cancer survivors, must be reassessed.

More than ever before, women today may have more information — and misinformation — about menopause.

Researchers at University of Waterloo have developed an artificial intelligence system, designed in combination with new MRI technology, to identify patients who might benefit from neoadjuvant chemotherapy for breast cancer.

High PD-L2 expression occurred in as many as one-third of previously untreated, ER-positive breast tumors and independently predicted early breast cancer recurrence, according to study results published in JCO Precision Oncology.

The FDA updated mammography regulations to require facilities to inform patients about their breast density, improve oversight and enforcement of facilities and aid physicians to better categorize and assess mammograms.

A cohort study published in JAMA Oncology found substantial state variations in racial and ethnic disparities in triple-negative breast cancer incidence, with Black women in four states having the highest rates.

Breast cancer stage and receptor status appeared to predict risk for recurrence among patients with stage I to stage III disease, according to study results published in Cancer.

Women using hormone therapy for menopause symptoms did not have a greater risk for lung cancer than their untreated peers, and may have had lower risk with higher HT dosage and duration, according to study data published in Menopause.

Researchers at Cleveland Clinic intend to expand their study of a novel vaccine designed to prevent triple-negative breast cancer.